IGF-1

The Central Longevity Paradox of IGF-1

IGF-1 sits at the intersection of two competing imperatives in longevity biology, and understanding both is essential for interpreting your result correctly.

In model organisms — worms, flies, mice — mutations that reduce IGF-1 signaling dramatically extend lifespan. The daf-2 mutation in C. elegans (which reduces IGF-1 receptor signaling) roughly doubles the worm's lifespan. IGF-1 pathway mutations in mice extend lifespan by 20–40%. These findings established IGF-1 as one of the most conserved aging-related pathways in biology, and generated significant interest in IGF-1 reduction as a longevity strategy. ¹

The problem is that humans are not worms or mice, and IGF-1 reduction in humans does not produce the same unambiguous benefit. In human populations, very low IGF-1 is consistently associated with sarcopenia, frailty, osteoporosis, cardiovascular disease, and cognitive decline — all of which reduce both lifespan and healthspan. Centenarian studies have found that long-lived individuals do not generally have suppressed IGF-1; some show high-normal levels. The picture is further complicated by the fact that IGF-1 is strongly anabolic — it is one of the primary signals for muscle protein synthesis — and that muscle mass is one of the strongest predictors of longevity in humans.

The current evidence-based position: for most adults, the longevity-optimal IGF-1 target is the upper-middle portion of the age-adjusted reference range — high enough to maintain muscle, bone, and cognitive function; not so high as to maximally stimulate cellular proliferation and suppress the cellular housekeeping mechanisms (autophagy, apoptosis) that clear damaged cells before they become problems.

What IGF-1 Does: Anabolic Effects and Cellular Signaling

IGF-1 exerts its effects by binding to the IGF-1 receptor (IGF-1R), which activates two primary intracellular signaling pathways: the PI3K-Akt-mTOR pathway (promoting cell growth, protein synthesis, and survival) and the MAPK/ERK pathway (promoting cell proliferation and differentiation).

In the context of healthy physiology and adequate exercise stimulus, these effects are largely beneficial:

• Skeletal muscle: IGF-1 is the primary hormonal signal for muscle protein synthesis and satellite cell activation — the stem cells that repair and grow muscle fibers after exercise. Without adequate IGF-1, muscle protein synthesis is impaired and sarcopenia progresses more rapidly.
• Bone: IGF-1 stimulates osteoblast activity (bone formation) and inhibits osteoclast activity (bone resorption). Low IGF-1 is a major driver of age-related bone loss and fracture risk.
• Brain: IGF-1 crosses the blood-brain barrier and supports neuronal survival, synaptic plasticity, and the production of brain-derived neurotrophic factor (BDNF). Low IGF-1 in older adults is associated with cognitive decline and increased Alzheimer's disease risk.
• Cardiovascular system: IGF-1 supports cardiac muscle mass and function, promotes endothelial nitric oxide production (vasodilation), and has anti-inflammatory effects in vascular tissue. Low IGF-1 is independently associated with heart failure and cardiovascular mortality.
• Metabolic function: IGF-1 enhances insulin sensitivity and glucose uptake in peripheral tissues. Low IGF-1 is associated with insulin resistance, and the two often decline together with aging and poor lifestyle.

The concern with chronically high IGF-1 operates through the same pathways. mTOR activation — IGF-1's primary downstream effector — promotes cellular growth but simultaneously suppresses autophagy, the cellular recycling process that clears damaged proteins and organelles. When mTOR is chronically elevated, cellular "garbage" accumulates, damaged mitochondria persist, and pre-cancerous cells are less likely to be cleared through apoptosis. These are the mechanisms proposed to explain the lifespan shortening seen with high IGF-1 signaling in animal models.

Age-Adjusted Reference Ranges: Why Context Is Everything

IGF-1 levels change dramatically across the lifespan, peaking during the adolescent growth spurt and declining progressively through adulthood. Interpreting an IGF-1 result without age-adjustment is meaningless — a level of 130 ng/mL is excellent for a 68-year-old and low for a 30-year-old.

The longevity-optimal targets represent the upper-middle portion of each age-adjusted range — roughly the 50th to 80th percentile for age. The goal is not to push IGF-1 to the top of the range at every age, but to prevent the excessive decline that is common in sedentary, protein-deficient, poorly sleeping adults and that significantly accelerates frailty and disease risk.

What Drives IGF-1: Lifestyle Factors That Matter

IGF-1 is one of the more modifiable hormonal biomarkers — meaningfully responsive to exercise, nutrition, sleep, and body composition. Understanding what raises and lowers it gives a clear optimization roadmap.

Factors that raise IGF-1

• Resistance training: Heavy compound exercise is the most potent non-pharmacological stimulus for IGF-1 production. Both the mechanical load on muscle tissue and the systemic GH pulse triggered by intense exercise drive hepatic IGF-1 synthesis. Even moderate resistance training 2–3 times per week produces measurable IGF-1 increases, particularly in older adults who tend to be most deficient.
• Adequate dietary protein: Protein intake directly regulates IGF-1 synthesis in the liver. Studies in both young and older adults demonstrate that very low protein diets suppress IGF-1 even in the presence of normal caloric intake. Leucine, the branched-chain amino acid most concentrated in meat, eggs, and dairy, is the primary trigger for the mTOR-mediated protein synthesis response and is particularly important for IGF-1 support. Current longevity medicine consensus targets 1.6–2.2 g of protein per kg of body weight in active adults, substantially higher than conventional dietary recommendations.
• Quality sleep: Approximately 70–80% of daily GH secretion occurs during the first two hours of deep (slow-wave) sleep. Sleep deprivation — whether from duration or quality — substantially suppresses GH pulses and consequently reduces IGF-1. Optimizing sleep is one of the highest-leverage interventions for maintaining GH/IGF-1 with aging.
• Healthy body composition: Visceral adiposity blunts hepatic GH receptor sensitivity, reducing IGF-1 production for any given GH pulse. Reducing visceral fat reliably raises IGF-1 in overweight adults even without other interventions.

Factors that lower IGF-1

• Caloric restriction and fasting: Energy restriction reliably reduces IGF-1, and this is proposed as one mechanism for fasting's longevity effects in animal models. The trade-off in humans is that prolonged caloric restriction also reduces muscle mass — making it a less clearly beneficial strategy than in model organisms.
• Low protein intake: Plant-based diets without adequate protein compensation, very low-calorie diets, and intentional protein restriction all lower IGF-1 substantially.
• Sedentary lifestyle: Physical inactivity reduces both the GH pulse amplitude and local IGF-1 production in muscle tissue.
• Alcohol: Chronic alcohol consumption reduces hepatic IGF-1 secretion and impairs GH receptor signaling.
• Liver disease: Because the liver is the primary site of IGF-1 production, any hepatic impairment reduces IGF-1 output.
• Hypothyroidism: Thyroid hormones modulate GH receptor expression in the liver. Hypothyroidism, including subclinical hypothyroidism, can reduce IGF-1 below what exercise and nutrition alone can compensate.

IGF-1, Cancer, and the Nuanced Risk Picture

The association between IGF-1 and cancer risk is real and worth understanding clearly, without overstating it. Multiple prospective cohort studies have found that IGF-1 in the upper quartile of the population distribution is associated with modestly increased risk of breast, prostate, and colorectal cancer — hazard ratios typically in the range of 1.2 to 1.8 compared to the lowest quartile. ²

Several important caveats are worth keeping in mind:

• The elevated cancer risk associated with high IGF-1 is concentrated at levels substantially above the longevity-optimal target range — generally above 200–220 ng/mL in older adults. Maintaining IGF-1 in the 120–180 ng/mL range does not appear to carry meaningful excess cancer risk compared to lower levels.
• The same population studies consistently show that low IGF-1 is associated with substantially increased cardiovascular mortality, frailty, and cognitive decline — risks that are typically larger in absolute terms for older adults than the modest cancer risk increase associated with mid-range IGF-1.
• IGF-1 likely does not initiate cancer, but may accelerate the growth of pre-existing cancer cells. The most prudent approach is to maintain IGF-1 in the middle of the age-appropriate range — not suppressed, not maximized — and to prioritize other cancer risk factors (inflammation, metabolic health, smoking, alcohol) that have larger effect sizes.
• The route to high IGF-1 matters. Exercise-driven IGF-1 elevation is likely more beneficial (and less concerning from a cancer risk standpoint) than IGF-1 elevated by exogenous GH administration, given the additional benefits of exercise on immune surveillance, inflammation, and tumor suppressor mechanisms.

How to Test IGF-1

IGF-1 is measured from a standard blood draw and does not require fasting. Unlike growth hormone itself, IGF-1 is stable throughout the day, so the timing of the blood draw does not meaningfully affect the result.

Always ensure the lab provides an age-adjusted reference range alongside the result — an absolute number without age context is difficult to interpret. If ordering through a direct-access service, confirm that age is entered correctly so the reference range reflects your actual age.

For a complete picture of GH axis function, pairing IGF-1 with IGFBP-3 (insulin-like growth factor binding protein 3) is useful. IGFBP-3 is the primary carrier protein for IGF-1 in the blood; the IGF-1:IGFBP-3 molar ratio reflects the bioavailable fraction of IGF-1 and can provide additional information when IGF-1 alone is ambiguous.

Retesting IGF-1 annually is appropriate for most adults as part of a comprehensive hormonal panel. If actively implementing a training or nutritional protocol to raise IGF-1, a 90-day retest captures enough time for meaningful change. IGF-1 responds more slowly than many biomarkers — significant changes typically take 8–16 weeks of consistent intervention to appear.

Sources

1. Kenyon C, et al. "A C. elegans Mutant That Lives Twice as Long as Wild Type." Nature, 1993. PubMed →
2. Renehan AG, et al. "Insulin-Like Growth Factor (IGF)-1, IGF Binding Protein-3, and Cancer Risk." Lancet, 2004. PubMed →
3. Sattler FR. "Growth Hormone in the Aging Male." Best Practice & Research Clinical Endocrinology & Metabolism, 2013. PubMed →